Revolution Medicines enters July with an unusually clear alignment between analyst conviction and options sentiment — both shifting decisively in the bulls' favour even as insiders quietly lock in gains.
The most striking development of the past week is the speed at which analysts have rerated the stock. Truist Securities raised its target to $210 on June 30, just six weeks after assuming coverage with a $179 target. Needham went further, lifting its target to $235 on June 29 — up from $183. Both kept Buy ratings. The moves follow a string of upgrades through June from Evercore ISI, RBC Capital, Oppenheimer, and HC Wainwright, all raising targets while maintaining positive ratings. The Street consensus now points to a mean target of $192.52, roughly in line with the current price of $187.28, but the trajectory matters more than the absolute level: nearly every analyst action over the past month has been upward. The one outlier is Bernstein, which initiated in late May at a cautious Market Perform with a $151 target — a useful reminder that not everyone is convinced the stock's 19% one-month rally is fully earned. The bull case centres on daraxonrasib's Phase 3 data in RAS-mutated pancreatic cancer and the potential to set a new standard of care. The bear case questions how much differentiation the molecule genuinely offers versus competitors and warns that the valuation — price-to-book at 19x and negative earnings — leaves little room for clinical setbacks.
Options traders have moved firmly in the same direction as the bulls. The put/call ratio closed at 0.49 on June 30, well below its 20-day average of 0.80, and more than one standard deviation below the mean. The shift is dramatic in context: from late May through mid-June, the PCR ran consistently above 1.0, reflecting roughly equal or heavier put demand. That regime ended abruptly around June 22, with call activity taking over as the stock broke higher. The 52-week PCR range runs from 0.16 to 2.23, so the current reading is toward the call-heavy end but not at an extreme — there is room for positioning to extend further if clinical newsflow remains positive ahead of the August 7 earnings date.
Short interest and borrow conditions tell a quieter story. Short interest runs at 6.6% of the free float — meaningful for a biotech, but not extreme, and roughly flat over the past month. Borrow availability is exceptionally loose at 1,591%, meaning there are far more shares available to lend than are currently borrowed; cost to borrow is just 0.50%, near the low end of the past year. There is no meaningful squeeze pressure here. The short score of 44 sits in the middle of the range, consistent with a stock that carries a watchable but not aggressive short base.
The insider picture adds a note of caution worth flagging. Over the two weeks ending June 24, multiple executives sold shares, including the COO (approximately $4.7 million), the CFO across four tranches totalling roughly $3.4 million), and the CEO ($1.6 million). The June 16 cluster saw the CEO, CFO, General Counsel, and two other officers all sell on the same day at the same price of $156.12 — consistent with scheduled plan sales at a pre-set trigger, though the timing as the stock pushed toward new highs is notable. The 90-day net figure is a positive $41.9 million, suggesting earlier buying still outweighs the recent selling in aggregate, but the recent pattern is one-way.
BlackRock added nearly 2.3 million shares through May, FMR (Fidelity) added 502,000, and UBS Asset Management added 1.45 million — a meaningful accumulation among large passive and active managers that supports the institutional bid beneath the stock. With Q2 results scheduled for August 7, the next meaningful test is whether daraxonrasib's Phase 3 readout timeline and any updated clinical data can sustain the analyst momentum that has driven targets sharply higher into the summer.
See the live data behind this article on ORTEX.
Open RVMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
